Sign in Subscribe
Genes

Breakthrough in Colon Cancer Prognosis: Developing a Predictive Gene Index

Strategic Insights

— 1 min read

Researchers at Sun Yat-sen University have made significant progress in identifying a predictive gene index for early-stage colorectal cancer (CRC) using a novel approach that integrates prognosis-related genes with immune-related gene signatures. The study, published in Translational Cancer Research, aims to provide a personalized gene index to estimate prognosis and aid in decision-making regarding adjuvant chemotherapy.

Key Takeaways:

  • A 10-gene pair index (GPI) was developed by integrating 309 prognostic-related genes with 463 immune-related genes, resulting in a 20-unique gene index that significantly stratified patients into high- and low-risk groups based on disease-free survival (DFS).
  • The GPI demonstrated robust predictive value, with a hazard ratio (HR) of 3.91 (95% CI: 2.36-6.5) for DFS among early-stage CRC patients, and area under the curve (AUC) values of 0.753, 0.770, and 0.775 at 2, 3, and 5 years, respectively.
  • Patients with adjuvant chemotherapy showed worse DFS than those without (HR =4.74, 95% CI: 2.28-9.82) among the GPI-identified low-risk group in early-stage CRC.
  • The GPI-identified high-risk group exhibited higher immune and stromal infiltration compared to the low-risk group.
  • Biological processes including apoptosis and angiogenesis were enriched among genes in the GPI, indicating its potential therapeutic implications.

Statistics:

  • 309 prognostic-related genes were integrated with 463 immune-related genes to construct the GPI.
  • The GPI consisted of 20 unique genes.
  • The study included a training cohort of 1,525 CRC patients and two validation cohorts.
  • DFS rates were significantly improved in GPI-identified low-risk group patients who did not receive adjuvant chemotherapy.
  • The GPI achieved higher accuracy (mean C-index, 0.81 vs. 0.65, P=0.03) compared to the commercialized Oncotype DX index.

Sources:

  • "Integrating Prognosis-related Genes With Immune-related Gene Signature for Development and Validation of a Survival Stratification Model for Early-stage Colorectal Cancer." Translational Cancer Research, 2025.
  • [Ame Publishing Company, Flat-Rm C 16F, Kings Wing Plaza 1, No 3 Kwan St, Shatin, Hong Kong 00000, Peoples R China]

Read more